ChemLifeIntelCHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
REGULATORY INTELLIGENCERecallNotable

Kroger 70% Isopropyl Alcohol Recalled Nationwide by Consumer Product Partners, LLC Over Cross-Contamination Concerns

MK
Meera KrishnanView Profile →
Senior Regulatory Intelligence Analyst
EXECUTIVE SUMMARY

Consumer Product Partners, LLC initiated a nationwide Class III recall (D-0660-2025) of Kroger 70% Isopropyl Alcohol due to cross-contamination. This event underscores critical supply chain vulnerabilities and the imperative for robust quality control, impacting procurement strategies and regulatory compliance for firms sourcing over-the-counter pharmaceuticals and chemicals.

Product Quality Breach: Kroger 70% Isopropyl Alcohol Recall Due to Cross-Contamination

Consumer Product Partners, LLC has initiated a voluntary, firm-initiated recall (D-0660-2025) of its Kroger 70% Isopropyl Alcohol, a human OTC drug, citing cross-contamination with other products as the primary reason. This Class III recall, effective from an initiation date of August 25, 2025, impacts 1,860 bottles distributed nationwide across the United States. The specific product affected is Lot 0662036, with an expiration date of June 19, 2027, packaged as NET WT 5.5 OZ (156 g) per can, NDC: 30142-810-14. The product, branded under The Kroger Co., Cincinnati, Ohio 45202, highlights the critical importance of stringent quality control in contract manufacturing and private label agreements. For procurement directors and supply chain VPs, this event signals an immediate need to review quality assurance protocols with all third-party manufacturers, especially for high-volume, low-cost items like isopropyl alcohol. Cross-contamination, even if classified as Class III (meaning the probability of serious adverse health consequences is remote), can lead to significant brand damage, costly product retrieval, and potential regulatory scrutiny. The recall of 1,860 bottles, while not massive in quantity, represents a failure in manufacturing controls that could have broader implications for consumer trust in the Kroger brand and its suppliers. Regulatory affairs heads must ensure that their firms' recall procedures are robust and can effectively manage nationwide distribution challenges, including rapid identification, isolation, and retrieval of affected product lots.

Recalling Firm Profile and Operational Impact: Consumer Product Partners, LLC

The recalling firm, Consumer Product Partners, LLC, located at 1 Swan Drive, Smyrna, TN 37167-2099, is responsible for this voluntary, firm-initiated recall. The FDA's Center Classification Date for this event was September 23, 2025, with the report date following on October 1, 2025, indicating the ongoing nature of the regulatory oversight. The initial firm notification method was a letter, demonstrating a proactive, albeit reactive, approach to addressing the quality deviation. While specific manufacturing facility details beyond the firm's address are not provided in the source, the incident underscores the operational challenges faced by companies involved in the production and distribution of over-the-counter pharmaceuticals. For business development executives and supply chain managers, this recall highlights the inherent risks in partnerships where a firm like Consumer Product Partners, LLC manufactures products distributed by a major retailer like The Kroger Co. The operational burden of managing a nationwide recall, from identifying affected inventory to coordinating reverse logistics and communicating with distributors and consumers, can be substantial. This event necessitates a re-evaluation of supplier due diligence processes, focusing not just on cost and capacity but critically on quality management systems and a track record of compliance. Firms must assess the financial and reputational resilience of their manufacturing partners to withstand such events, ensuring business continuity and brand protection.

Supply Chain and Market Exposure: Nationwide Distribution and Brand Risk for Kroger

The recalled Kroger 70% Isopropyl Alcohol was distributed nationwide across the US, indicating a broad market exposure for this quality incident. As a private label product, the brand reputation of The Kroger Co. is directly implicated, even though Consumer Product Partners, LLC is the recalling firm. Kroger is a prominent retailer, and any quality issue with its branded products can significantly erode consumer trust and market share, particularly in the competitive over-the-counter drug segment. The product's generic name, Isopropyl Rubbing Alcohol, and substance name, Isopropyl Alcohol (UNII: ND2M416302), signify its common use, making the cross-contamination issue a concern for a wide consumer base. Procurement directors must recognize that private label agreements, while offering margin benefits, transfer significant brand risk. This incident demands a rigorous review of contractual obligations, indemnification clauses, and quality control oversight mechanisms within all private label manufacturing partnerships. Supply chain VPs should assess their ability to trace and retrieve products across a nationwide distribution network efficiently, understanding the logistical complexities and costs associated with such an extensive recall. The impact extends beyond the immediate product; it can influence consumer perception of all Kroger-branded health and wellness products, potentially leading to a broader decline in sales if not managed transparently and effectively. Business development executives should consider the long-term implications for retailer-supplier relationships and the importance of robust quality metrics in future partnership evaluations.

Regulatory Compliance and Future Outlook: Managing Recall Remediation

The ongoing status of recall D-0660-2025 signifies that Consumer Product Partners, LLC is actively engaged in the remediation process under FDA oversight. A Class III recall, while indicating a low probability of serious health consequences, still requires thorough investigation into the root cause of the cross-contamination and implementation of corrective and preventive actions (CAPA). The firm's recall initiation date of August 25, 2025, and the subsequent FDA classification and report dates, underscore the structured process for managing such events. Regulatory affairs heads must ensure that all documentation related to the root cause analysis, CAPA implementation, and effectiveness checks is meticulously prepared and submitted to the FDA. For firms operating in the chemical and life sciences industry, this event serves as a reminder that even voluntary recalls can lead to heightened regulatory scrutiny. The FDA will monitor the effectiveness of the recall and the adequacy of the firm's corrective actions. Failure to address the underlying quality system deficiencies could result in further regulatory actions, including potential Warning Letters or increased inspections in the future. Supply chain VPs should anticipate potential disruptions to future product availability from Consumer Product Partners, LLC as the firm dedicates resources to remediation. Proactive engagement with regulatory bodies and transparent communication are crucial for mitigating long-term impacts on a company's regulatory standing and market access.

Strategic Sourcing Considerations for Isopropyl Alcohol and OTC Chemicals

The recall of Kroger 70% Isopropyl Alcohol due to cross-contamination necessitates a strategic re-evaluation of sourcing practices for common chemicals and over-the-counter (OTC) drug components. While the specific alternative suppliers are not detailed in the available knowledge graph, procurement directors should immediately initiate a review of their approved vendor lists for Isopropyl Alcohol and similar excipients or active pharmaceutical ingredients (APIs). Key considerations include geographical diversity of suppliers to mitigate regional supply chain disruptions, robust supplier qualification programs that include on-site audits, and comprehensive quality agreements that detail specifications, testing protocols, and change control procedures. Business development executives should recognize that reliance on a single source or a limited number of suppliers for critical materials, even seemingly simple ones like Isopropyl Alcohol, introduces significant risk. Diversifying the supplier base not only enhances supply chain resilience but also provides leverage in maintaining quality standards. Qualification timelines for new suppliers can range from several months to over a year, depending on the complexity of the material and regulatory requirements. Therefore, proactive identification and qualification of secondary and tertiary suppliers are essential. This incident underscores that even for widely available chemicals, a lapse in quality control at a single manufacturing site can have widespread commercial and reputational repercussions, demanding a multi-faceted risk mitigation strategy.

Broader Industry Context: Parallel Quality Control Challenges and Regulatory Trends

This recall of Kroger 70% Isopropyl Alcohol by Consumer Product Partners, LLC occurs within a broader industry landscape marked by ongoing quality control challenges. Recent parallel events, such as Essential Wellness Pharma's Class II recall of Progesterone Injection due to sterility assurance failures (June 15, 2026), and the FDA hearing on Amgen's Tavneos market future amid independent data review (June 15, 2026), highlight a persistent focus by the FDA on manufacturing quality and product integrity across the pharmaceutical and life sciences sectors. While these events involve different companies and products, they collectively signal an environment of heightened regulatory scrutiny over manufacturing processes and product quality. For regulatory affairs heads and quality assurance leaders, these trends emphasize the need for continuous improvement in quality management systems. The financial and reputational costs associated with recalls, even for Class III products, are substantial. Proactive investment in advanced manufacturing technologies, robust quality by design (QbD) principles, and comprehensive employee training programs are no longer optional but essential for maintaining market access and competitive advantage. Supply chain VPs must integrate these regulatory trends into their risk assessments, understanding that quality failures at any point in the supply chain can trigger significant business disruption and regulatory intervention, impacting product availability and market confidence.

ChemLifeIntel analysis · Meera Krishnan. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — covering 1,200+ pharmaceutical and chemical companies across the global value chain.

Covering 1,200+ pharmaceutical and chemical companies across the global value chain
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
3d ago

CDSCO Enacts Sweeping Regulatory Changes Across India's Pharma and Medical Device Sectors

India's CDSCO has issued numerous critical regulatory updates, impacting drug formulations, medical devices, and animal health. These changes, including product restrictions, revised fees, and new import rules, necessitate immediate review by procurement, regulatory affairs, and supply chain leaders to maintain compliance and mitigate operational risks across the Indian market.

REGULATORY INTELLIGENCE
3d ago

ANSM Fines Novo Nordisk and Eli Lilly for GLP-1 Obesity Campaign Breaches, Novo Nordisk Explores Legal Challenge

France's ANSM has fined Novo Nordisk and Eli Lilly for obesity campaign breaches related to GLP-1 analogue misuse. This action underscores escalating regulatory scrutiny on high-demand drug marketing. Novo Nordisk is considering a legal challenge, signaling potential prolonged legal and reputational impacts for major pharmaceutical players in the European market.

REGULATORY INTELLIGENCE
4d ago

FDA Faces Pressure to Restrict Livestock Antibiotic Use: Major Commercial Implications for Chemical and Life Sciences

Over 60 organizations have petitioned the FDA to revoke approvals for antibiotic use in livestock for disease prevention and growth promotion. This action, driven by concerns over antibiotic resistance and its human health toll, signals potential significant regulatory shifts. Procurement, supply chain, and regulatory affairs leaders must prepare for market disruption and new compliance requirements.

REGULATORY INTELLIGENCE
4d ago

Germany Abandons Branded Pharmaceutical Price Reduction Plan Amid Industry Opposition

Germany has reversed its decision to implement a variable pricing structure aimed at reducing branded pharmaceutical costs, following significant criticism from drug manufacturers. This move signals a crucial win for pharmaceutical companies, preserving current revenue models and mitigating potential market access challenges in one of Europe's largest economies. Procurement and regulatory teams should reassess their German market strategies.

REGULATORY INTELLIGENCE
4d ago

Health Canada's Drug Product Database: A Critical Resource for Market Intelligence and Regulatory Compliance

Health Canada's Drug Product Database (DPD), last updated March 1, 2019, offers vital intelligence for market access and regulatory compliance. This comprehensive online tool allows stakeholders to query drug identification numbers (DINs), ATC codes, and company data. For procurement, regulatory, and business development executives, the DPD is indispensable for strategic planning and risk management within the Canadian pharmaceutical landscape.

REGULATORY INTELLIGENCE
4d ago

CDSCO Authorizes Oseltamivir Outlets: Clarifying India's Supply Channels for H1N1 Antivirals

India's CDSCO has published a list of authorized outlets for oseltamivir formulation, critical for H1N1 swine flu. This action clarifies legitimate supply channels for this Schedule X drug, signaling intensified regulatory oversight in India's pharmaceutical sector. Procurement and supply chain leaders must ensure compliance with these defined distribution networks to mitigate risks and maintain market access.

REGULATORY INTELLIGENCE
5d ago

Express Scripts, PCMA Challenge Tennessee's FAIR Rx Act: PBM Vertical Integration Under Threat

Express Scripts and the PCMA are challenging Tennessee's FAIR Rx Act, a law prohibiting PBMs from owning pharmacies and restricting mail-order services. This follows CVS Caremark's similar lawsuit. If upheld, the law, effective 2028, threatens to close PBM-affiliated pharmacies, disrupt national drug supply chains, and impede patient access, impacting hundreds of thousands. This legal battle signals escalating state-level pressure on PBM business models.

REGULATORY INTELLIGENCE
6d ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
6d ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

REGULATORY INTELLIGENCE
6d ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
6d ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
6d ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

ENTITY HUBS

Entities in this Brief

Camber Consumer Care
company hub
Open company hub
Wish Isopropyl Alcohol
molecule hub
Open molecule hub